Seeking Turnaround, Myrexis Taps Two New Execs
This article was originally published in The Pink Sheet Daily
Executive Summary
Rather than pursue a sale, Myrexis will obtain revenue-generating drugs that it feels are underperforming in other hands. Until it chooses an asset to acquire, it will operate as a virtual company.
You may also be interested in...
A New Chapter, A New CEO For Dendreon
Former Savient and ImClone CEO Johnson will be responsible for driving commercial expansion of Provenge in the U.S. and Europe. Mitchell Gold steps down as CEO after successfully getting the prostate cancer drug to market following an arduous FDA review but struggling with commercial complexities.
J&J Buys Scios: Will Natrecor Make Another Centocor?
Johnson & Johnson will gain access to Scios' Phase II oral rheumatoid arthritis program through its proposed $2.4 bil. acquisition of the biotech company
Craig Venter Wants To Extend Your Life (And Own Your Data)
The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.